Pricing Log in Create free account
Friday 6 November 2026 Export GMAB’s income statement to Excel — free account

Genmab A/S Sponsored ADR

GMAB Healthcare Biotechnology

Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.

Revenue
+24.9%
EPS
−9.26%
Free cash flow
−7.69%

Quarter to June 2026, against a year earlier

53.35 0.61 +1.16%
Market cap
$31.5B
P/E
41.7×
Fwd P/E
47.3×
Dividend yield
—
F-score
4/9
Altman Z
2.78
Beneish M
−3.00
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 4.28%

Capital & Financial Ratios $m

Size
Market Cap 31,510.00
Revenue ttm 4,131.00
Net income ttm 906.00
Free cash flow ttm (6,347.00)
Net debt Q 3,632.00
Valuation
P/E 41.72 (above 35: high)
Forward P/E 47.30 (above 35: high)
Price / sales 7.87
Forward P/S Powerpack
Price / FCF 0.00
Price / book 5.46
Financial health
Current ratio Q 2.46 (at or above 1.5: strong)
Debt / equity Q 0.86
Interest coverage Q 2.70
Growth
Revenue growth Q +24.86% (above 0%: growing)
Operating income growth Q +4.17% (above 0%: growing)
EPS, this year −21.93% (below 0%: weak)
EPS, next year A +45.64% (at or above 15%: strong)
Revenue, next year A +20.78% (at or above 10%: strong)
EPS, past 5 yrs +6.58%
EPS, next 5 yrs A +22.10% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 8.7×, against a ten-year median of 10.3×; over the ten years it ranged from 2.9× in 2025 to 24.0× in 2019.
P/E against its own 10 years 87.52%
10-year low 10-year high
P/S against its own 10 years 38.47%
10-year low 10-year high
P/B against its own 10 years 45.95%
10-year low 10-year high
EV/Sales against its own 10 years 43.73%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 4,085 2,954 1,715 1,503
Receivables 718 937 1,152 1,280
Inventory 8 9 18 18
Other — — — —
4,812 3,900 2,885 2,801
2023 2024 2025 Q'26
Payables — — — —
ST’ Debt — — 273 294
Other — 3 24 21
361 744 1,427 1,140

Compound Annual Growth %

10y 5y 3y
Sales — 19.15% 21.64%
Cash Flow — 3.77% 28.89%
Earnings — 5.73% 7.19%
Book Value — 14.82% 14.59%

Earnings Trends EPS, adjusted, against the consensus

Jun 2026 Estimate 0.37 Actual 0.54

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Sep 2025 0.48 0.65 Beat by 0.17
Dec 2025 0.46 0.05 Miss by 0.41
Mar 2026 0.15 0.15 Met by 0.00
Jun 2026 0.37 0.54 Beat by 0.17
Sep 2026 0.36 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.08 0.49 — — —
’25 0.31 0.54 0.65 0.05 1.54
’24 0.29 0.31 0.29 0.85 1.76
’23 0.05 0.30 0.47 0.14 0.96
’22 0.11 0.41 0.53 0.12 1.15
’21 0.27 0.08 0.21 0.17 0.72
’20 0.06 0.76 0.13 0.14 1.12
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 896 1,155 — — —
’25 715 925 1,022 1,058 3,720
’24 603 779 816 923 3,121
’23 411 613 693 675 2,392
’22 320 452 553 742 2,067
’21 256 320 366 407 1,349
’20 132 805 271 341 1,549
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 3 51 — — —
’25 287 62 536 301 1,186
’24 219 219 299 389 1,126
’23 466 70 297 238 1,072
’22 89 133 254 78 554
’21 192 58 66 39 354
’20 324 (6) 817 (150) 986
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) 48 — — —
’25 257 52 534 (6,927) (6,084)
’24 215 215 292 346 1,055
’23 451 54 283 219 1,017
’22 80 123 244 17 509
’21 188 45 54 18 314
’20 315 (27) 808 (166) 939
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 258 381 479 804 1,549 1,349 2,067 2,392 3,121 3,720 4,131 +34.5% 4,493 5,408 7,011 +23.5%
Gross margin, % 0.00 0.00 100.00 100.00 100.00 100.00 100.00 98.63 95.42 93.60 93.03 +93.6 pt
EBT 160 171 255 429 904 634 996 818 1,326 1,204 906 +25.1%
EBT margin, % 62.22 44.99 53.29 53.28 58.39 46.96 48.20 34.22 42.49 32.37 21.93 (29.8) pt
Net income 168 0 255 429 904 634 996 818 1,326 1,204 906 +24.4%
Per share, $
Per share, $ Revenue 0.43 0.62 0.78 1.28 2.38 2.06 3.16 3.66 4.86 5.99 6.74 +34.1%
Earnings 0.28 0.29 0.38 0.52 1.12 0.73 1.16 0.97 1.77 1.55 1.27 +21.0%
Cash flow 0.08 0.41 0.26 0.32 1.51 0.54 0.85 1.64 1.75 1.91 1.45 +42.9%
Capex 0.00 0.00 (0.12) (0.03) (0.07) (0.06) (0.07) (0.08) (0.11) (11.70) (11.80) n/m
Free cash flow 0.08 0.41 0.14 0.29 1.44 0.48 0.78 1.56 1.64 (9.79) (10.35) n/m
Book value 1.13 1.63 2.07 3.34 4.49 5.40 5.94 7.03 8.00 9.41 9.71 +26.5%
Shares, m 604 619 613 630 652 654 654 653 642 622 620 +0.3%
Valuation, ×
Valuation, × P/E 6.11 2.99 7.73 33.54 36.96 53.46 36.47 33.10 11.79 19.87 41.72 24.2
P/S 0.00 0.00 0.00 17.48 17.11 19.17 13.61 8.77 4.29 5.15 7.87 8.6
P/B 0.81 0.81 0.81 6.68 9.05 7.33 7.24 4.57 2.61 3.27 5.46 4.3
EV/Sales 0.00 0.00 0.00 15.47 15.55 16.94 12.13 7.11 3.38 6.10 8.75 7.7
EV/FCF 0.00 0.00 0.00 34.61 25.89 77.35 55.29 17.66 9.88 (3.73) (5.69) 21.7
Cash, $m
Cash, $m Operating cash flow 47 256 161 199 986 354 554 1,072 1,126 1,186 891 +43.3%
Capex (5) (14) (76) (17) (47) (40) (45) (55) (71) (7,270) (7,238) +126.2%
Free cash flow 47 256 85 182 939 314 509 1,017 1,055 (6,084) (6,347) n/m
Balance, $m
Balance, $m Working capital 636 923 1,107 1,952 2,687 3,368 3,760 4,451 3,156 1,458 1,661 +9.7%
Net debt (556) (873) (967) (1,617) (2,411) (3,012) (3,075) (4,085) (2,954) 3,559 3,632 n/m
Shareholders’ equity 685 1,010 1,269 2,106 2,929 3,531 3,886 4,590 5,137 5,847 5,957 +26.9%
Returns, %
Returns, % ROA 18.64 47.86 22.39 17.99 26.46 13.37 19.06 13.43 19.64 9.99 8.30 (8.6) pt
ROIC 0.00 0.00 45.21 50.60 116.54 57.78 69.44 95.70 27.83 7.08 6.99 +7.1 pt
ROE 19.87 20.98 20.46 19.24 28.95 14.81 21.08 14.91 23.30 17.53 14.00 (2.3) pt
People
People Employees — — 419 548 781 1,212 1,660 2,204 2,682 3,029 — +32.7%
Revenue/emp, $m 0.00 0.00 1.14 1.47 1.98 1.11 1.24 1.09 1.16 1.23 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Genmab A/S Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ONC BeOne Medicines Ltd. - Sponsored ADR $40.4B 65.9× 48.8× +33.81% (above 0%: growing) +143.68% (above 0%: growing) +33.59% (above 0%: growing) 88.52% 22.15% Compare
RPRX Royalty Pharma PLC $39.0B 44.8× 27.3× +13.26% (above 0%: growing) −51.52% (below 0%: shrinking) +364.63% (above 0%: growing) 100.00% 59.53% Compare
RVMD Revolution Medicines, Inc. $38.1B — (loss-making) — (loss-making) +1,188.71% (above 0%: growing) n/m −99.06% (below 0%: shrinking) 100.00% (188.88%) Compare
GMAB Genmab A/S Sponsored ADR $31.5B 41.7× 47.3× +24.86% (above 0%: growing) −9.26% (below 0%: shrinking) −7.69% (below 0%: shrinking) 92.73% 32.47%
ROIV Roivant Sciences Ltd. $26.5B — (loss-making) — (loss-making) −33.55% (below 0%: shrinking) n/m −29.99% (below 0%: shrinking) 80.31% (25,380.93%) Compare
INCY Incyte Corporation $24.1B 56.3× 55.6× +14.00% (above 0%: growing) n/m −232.97% (below 0%: shrinking) 93.02% (45.49%) Compare
INSM Insmed, Inc. $23.9B — (loss-making) — (loss-making) +268.43% (above 0%: growing) n/m +81.06% (above 0%: growing) 85.09% (17.04%) Compare
BNTX BioNTech SE Sponsored ADR $21.6B — (loss-making) — (loss-making) −16.42% (below 0%: shrinking) n/m −123.82% (below 0%: shrinking) 91.99% 9.70% Compare
ALNY Alnylam Pharmaceuticals, Inc. $21.0B 7.9× 13.5× +16.74% (above 0%: growing) +747.64% (above 0%: growing) −4.76% (below 0%: shrinking) 75.19% 23.72% Compare
Median of peers $25.3B 50.6× 38.1× +15.37% +143.68% −17.38% 90.26% (3.67%)

All 621 Biotechnology stocks →

Genmab A/S Sponsored ADR (GMAB) Latest News

6 Nov

Impact 4 · · The Motley Fool transcript
Impact 3 · · GuruFocus.com

5 Nov

Impact 3 · · MarketBeat transcript
Impact 3 · · Investing.com
Impact 3 · · GlobeNewswire

29 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · clinicaltrialsarena.com
Impact 4 · · biopharmadive.com

28 Oct

Impact 4 · · MarketBeat
Impact 4 · · Benzinga
Impact 4 · · Stocktwits
Impact 4 · · Investing.com
Impact 4 · · Business Wire

27 Oct

Impact 4 · · Investing.com

26 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · Benzinga
Impact 4 · · Zacks
Impact 4 · · Business Wire
Impact 4 · · Investing.com

25 Oct

Impact 4 · · GlobeNewswire
Impact 4 · · Business Wire

24 Oct

Impact 4 · · Business Wire
Impact 4 · · Business Wire
Impact 3 · · Simply Wall St.
Impact 3 · · Simply Wall St.

23 Oct

Impact 4 · · Investing.com
Impact 4 · · Business Wire
Impact 4 · · GlobeNewswire

15 Oct

Impact 4 · · Simply Wall St.

13 Oct

Impact 4 · · GlobeNewswire

GMAB metrics, ten years each

stockrow.com/GMAB · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com